Virtus ETF Advisers’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,958
| Closed | -$258K | – | 391 |
|
|
2021
Q3 | $258K | Sell |
2,958
-271
| -8% | -$23.6K | 0.11% | 216 |
|
|
2021
Q2 | $500K | Buy |
3,229
+550
| +21% | +$85.2K | 0.21% | 150 |
|
|
2021
Q1 | $423K | Buy |
2,679
+73
| +3% | +$11.5K | 0.18% | 171 |
|
|
2020
Q4 | $605K | Buy |
2,606
+273
| +12% | +$63.4K | 0.25% | 112 |
|
|
2020
Q3 | $511K | Buy |
2,333
+196
| +9% | +$42.9K | 0.27% | 131 |
|
|
2020
Q2 | $607K | Sell |
2,137
-205
| -9% | -$58.2K | 0.29% | 115 |
|
|
2020
Q1 | $675K | Sell |
2,342
-198
| -8% | -$57.1K | 0.28% | 138 |
|
|
2019
Q4 | $730K | Sell |
2,540
-410
| -14% | -$118K | 0.12% | 154 |
|
|
2019
Q3 | $426K | Sell |
2,950
-164
| -5% | -$23.7K | 0.09% | 186 |
|
|
2019
Q2 | $280K | Buy |
3,114
+1,288
| +71% | +$116K | 0.06% | 248 |
|
|
2019
Q1 | $160K | Sell |
1,826
-222
| -11% | -$19.5K | 0.34% | 94 |
|
|
2018
Q4 | $288K | Buy |
2,048
+299
| +17% | +$42K | 0.05% | 127 |
|
|
2018
Q3 | $447K | Sell |
1,749
-1,250
| -42% | -$319K | 0.05% | 140 |
|
|
2018
Q2 | $764K | Sell |
2,999
-2,423
| -45% | -$617K | 0.68% | 57 |
|
|
2018
Q1 | $1.09M | Buy |
5,422
+2,957
| +120% | +$595K | 0.95% | 28 |
|
|
2017
Q4 | $355K | Buy |
2,465
+80
| +3% | +$11.5K | 0.45% | 82 |
|
|
2017
Q3 | $393K | Buy |
2,385
+218
| +10% | +$35.9K | 0.05% | 113 |
|
|
2017
Q2 | $294K | Buy |
2,167
+143
| +7% | +$19.4K | 0.04% | 129 |
|
|
2017
Q1 | $390K | Buy |
2,024
+194
| +11% | +$37.4K | 0.07% | 115 |
|
|
2016
Q4 | $258K | Sell |
1,830
-211
| -10% | -$29.7K | 0.08% | 133 |
|
|
2016
Q3 | $298K | Hold |
2,041
| – | – | 0.14% | 100 |
|
|
2016
Q2 | $205K | Buy |
2,041
+846
| +71% | +$85K | 0.15% | 134 |
|
|
2016
Q1 | $160K | Buy |
+1,195
| New | +$160K | 0.22% | 113 |
|